Health Score

0 Excellent

Metadata coverage

Abstract

ORCID

References

License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder

Award / grant

Affiliation & institutional identifiers

Affiliation

ROR ID

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

Attach ORCID iDs across 16 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Low impact16 DOIs

Deposit reference lists for 15 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact15 DOIs

Add abstracts to 9 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact9 DOIs

DOIs for this ISSN

Showing the top 5 of 149 DOIs, ordered by correction priority.

#	Title	Missing	Priority	Citations
1	Adrenocortical cancer recurrence following initial transcuta… (10.1530/eo-21-0031)	References ORCID	47.71	8
2	Epidemiology of craniopharyngiomas: a population-based study… (10.1530/eo-21-0006)	References ORCID	38.91	5
3	Pituitary tumors and the risk of other malignancies: is the… (10.1530/eo-21-0033)	ORCID	30.76	16
4	Investigating the clinical, pathological and molecular profi… (10.1530/eo-21-0011)	References ORCID	30.10	3
5	FOXE1 polymorphism rs965513 predisposes to thyroid cancer in… (10.1530/eo-21-0003)	References	15.05	3
6	Hypoxia stimulates angiogenesis and a metabolic switch in hu… (10.1530/eo-21-0014)	References ORCID	15.05	1
7	<i>Endocrine Oncology</i> : the home for… (10.1530/eo-23-0012)	Abstract References	15.05	1
8	Acknowledgement to reviewers (10.1530/eo-2-a1)	Abstract References ORCID	0.00	0
9	The expanding role of hormones in cancer (10.1530/eo-21-0001)	Abstract References ORCID	0.00	0
10	Serum osteopontin can improve papillary thyroid cancer risk… (10.1530/eo-21-0005)	References ORCID	0.00	0
11	SAKK 21/12: a phase II trial of transdermal CR1447 in breast… (10.1530/eo-21-0009)		0.00	3
12	cfDNA in pancreatic neuroendocrine carcinoma management with… (10.1530/eo-21-0012)	References ORCID	0.00	0
13	Characterization of hyperlipidemia secondary to mitotane in… (10.1530/eo-21-0021)		0.00	5
14	Potential pitfalls in diagnosis of immunotherapy-induced hyp… (10.1530/eo-21-0023)		0.00	1
15	Low but not undetectable early postoperative nadir serum cor… (10.1530/eo-21-0026)		0.00	5
16	Dopamine agonist therapy for prolactinomas: do we need to re… (10.1530/eo-21-0038)		0.00	35
17	Clinical presentation of sporadic and hereditary pheochromoc… (10.1530/eo-22-0040)		0.00	2
18	Pituitary carcinoma: reclassification and implications in th… (10.1530/eo-22-0041)		0.00	9
19	Molecular mechanisms involved in somatostatin receptor regul… (10.1530/eo-22-0042)		0.00	3
20	Pancreatic neuroendocrine neoplasms: survival trend analysis… (10.1530/eo-22-0043)		0.00	2
21	Pheochromocytoma and paraganglioma: germline genetics and he… (10.1530/eo-22-0044)		0.00	37
22	Hypoparathyroidism: an uncommon adverse effect of treatment… (10.1530/eo-22-0047)		0.00	5
23	Diverse role of androgen action in human breast cancer (10.1530/eo-22-0048)		0.00	7
24	Adjuvant therapy in adrenocortical carcinoma: prognostic fac… (10.1530/eo-22-0050)		0.00	11
25	Synchronous AML and pancreatic neuroendocrine neoplasm, both… (10.1530/eo-22-0052)		0.00	1
26	Role of filamin A in the pathogenesis of neuroendocrine tumo… (10.1530/eo-22-0055)		0.00	10
27	Hyponatraemia and the syndrome of inappropriate antidiuresis… (10.1530/eo-22-0056)		0.00	17
28	Regulatory genes in the androgen production, uptake and conv… (10.1530/eo-22-0058)		0.00	6
29	Visualization of the protein–protein interactions of hormone… (10.1530/eo-22-0059)		0.00	2
30	Transient remission of hyperparathyroidism after fine-needle… (10.1530/eo-22-0060)		0.00	3
31	Kinase inhibitors in thyroid cancers (10.1530/eo-22-0062)		0.00	3
32	Unusual presentation of lung carcinoma with pituitary metast… (10.1530/eo-22-0064)		0.00	2
33	Cellular specificity of androgen receptor, coregulators, and… (10.1530/eo-22-0065)		0.00	13
34	Tumour volume is a predictor of lymphovascular invasion in d… (10.1530/eo-22-0066)		0.00	1
35	Potential pitfalls in diagnosis of immunotherapy-induced hyp… (10.1530/eo-22-0069)	Abstract	0.00	0
36	The role of 11-oxygenated androgens in prostate cancer (10.1530/eo-22-0072)		0.00	2
37	Curcumin effects on Leydig cell functions and potential ther… (10.1530/eo-22-0075)		0.00	1
38	The role of serotonin inhibition within the treatment of car… (10.1530/eo-22-0077)		0.00	10
39	Thrombotic microangiopathy associated with lenvatinib therap… (10.1530/eo-22-0078)		0.00	3
40	The evolution in pituitary tumour classification: a clinical… (10.1530/eo-22-0079)		0.00	7
41	Paragangliomas of the head and neck: a contemporary review (10.1530/eo-22-0080)		0.00	23
42	Cabergoline-associated valvulopathy of the tricuspid valve i… (10.1530/eo-22-0086)		0.00	2
43	Germline genetic variants in pheochromocytoma/paraganglioma:… (10.1530/eo-22-0091)		0.00	10
44	Succinate dehydrogenase variants in paraganglioma: why are B… (10.1530/eo-22-0093)		0.00	0
45	Exploring genetic loci of type 2 diabetes and cancer: a revi… (10.1530/eo-22-0094)		0.00	2
46	Lobectomy and completion thyroidectomy rates increase after… (10.1530/eo-22-0095)		0.00	3
47	Ectopic ACTH Cushing's syndrome caused by a large-cell neuro… (10.1530/eo-23-0002)		0.00	0
48	The role of DNA methylation in human pancreatic neuroendocri… (10.1530/eo-23-0003)		0.00	2
49	Metyrosine-associated endocrinological changes in pheochromo… (10.1530/eo-23-0006)		0.00	3
50	Peptides disrupting TM4SF3 interaction with AR or AR-V7 bloc… (10.1530/eo-23-0010)		0.00	0